ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer

Recruiting Observational Study
Biliary Tract Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
CHA University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This prospective, multicenter, observational study aims to evaluate the role of circulating tumor DNA (ctDNA) in advanced or metastatic biliary tract cancer (BTC) patients in Korea. Tissue-based genomic profiling is often limited due to the anatomical challenges of tumor biopsy and insufficient DNA quality. ctDNA analysis offers a minimally invasive alternative for identifying actionable genetic a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Histologically confirmed advanced or metastatic biliary tract cancer (including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder carcinoma) * Patients meeting one of the following conditions: * Prior to initiation of first-line systemic ther…
Contacts

Hong Jae Chon, MD. PhD

82-31-780-3928

minidoctor@cha.ac.kr

CONTACT

Hong Jae Chon, MD. PhD

82-31-780-3928

hongjaechon@gmail.com

CONTACT